

Supplementary Online Content

Bernstein AN, Talwar R, Handorf E, et al. Assessment of prostate cancer treatment among Black and White patients during the COVID-19 pandemic. *JAMA Oncol*.

Published online July 22, 2021. doi:10.1001/jamaoncol.2021.2755

eFigure. Cohort Design


eTable 1. Patient Demographics and Clinical Characteristics for Patients With Untreated Non-metastatic Prostate Cancer Prior to the 2020 COVID-19 Pandemic

eTable 2. Univariable Logistic Regression Analysis for Predictors of Surgery During the 2020 COVID-19 Lockdown and Prior Period in Patients With Untreated Non-metastatic Prostate Cancer

eTable 3. Rates of Non-Surgical Treatment Prior to and During the 2020 Lockdown, by Race

This supplementary material has been provided by the authors to give readers additional information about their work.

eFigure. Cohort Design



eTable 1. Patient Demographics and Clinical Characteristics for Patients With Untreated Non-metastatic Prostate Cancer Prior to the 2020 COVID-19 Pandemic

		Black, Non-Hispanic	White, Non-Hispanic	p-value
		96	282	
Age at Presentation	Under 60	30 (31.2%)	57 (20.2%)	0.037
	60-69	41 (42.7%)	157 (55.7%)	
	70-79	20 (20.8%)	62 (22.0%)	
	80+	5 (5.2%)	6 (2.1%)	
Covid-19 Severity Risk Factors	No Risk Factors	8 (8.3%)	20 (7.1%)	0.73
	1 Risk Factors	45 (46.9%)	123 (43.6%)	
	2 or more Risk Factors	43 (44.8%)	139 (49.3%)	
Obese		41 (42.7%)	128 (45.4%)	0.65
Cardiovascular Disease		5 (5.2%)	13 (4.6%)	0.81
Diabetes		25 (26.0%)	30 (10.6%)	<0.001
Chronic Pulmonary Disease		2 (2.1%)	11 (3.9%)	0.4
High Risk Prostate Cancer		28 (29.2%)	72 (25.5%)	0.49
PSA Prior to Biopsy, median (IQR)		7.7 (5.1, 11.2)	6 (4.4, 8.6)	0.001
Clinical T Stage	I	71 (74.0%)	224 (79.4%)	0.12
	II	21 (21.9%)	55 (19.5%)	
	III	4 (4.2%)	3 (1.1%)	
Biopsy Gleason Grade Group	1	19 (19.8%)	74 (26.2%)	0.35
	2	30 (31.2%)	94 (33.3%)	
	3	24 (25.0%)	50 (17.7%)	
	4 & 5	23 (24.0%)	64 (22.7%)	
MRI during Work Up		49 (51.0%)	180 (63.8%)	0.027
Outside Biopsy		39 (40.6%)	139 (49.3%)	0.14
Prostatectomy during lockdown reference period		17 (17.7%)	54 (19.1%)	0.75
Prostatectomy during reopening reference period*		24(25.0%)	61 (21.6%)	0.49
Practice Site	A	18 (18.8%)	43 (15.2%)	<0.001
	B	1 (1.0%)	58 (20.6%)	
	C	28 (29.2%)	109 (38.7%)	
	D	32 (33.3%)	62 (22.0%)	
	E	17 (17.7%)	10 (3.5%)	

*Limited to sites with mature extended data collection

eTable 2. Univariable Logistic Regression Analysis for Predictors of Surgery During the 2020 COVID-19 Lockdown and Prior Period in Patients With Untreated Non-metastatic Prostate Cancer

		2019			2020		
		OR	95% CI	p-value	OR	95% CI	p-value
Age at Presentation	Under 60	Reference			Reference		
	60-69	0.7	(0.4 - 1.2)	0.17	1.2	(0.6 - 2.6)	0.56
	70-79	0.6	(0.3 - 1.2)	0.13	1.2	(0.5 - 2.9)	0.63
	80+	----			----		
Race	Black, non-Hispanic	Reference			Reference		
	White, non-Hispanic	1.1	(0.6 - 2.0)	0.76	26.2	(3.6 - 193.6)	<0.001
Covid-19 Severity Risk Factors	No Risk Factors	Reference			Reference		
	1 Risk Factors	1.4	(0.5 - 3.9)	0.53	1.4	(0.5 - 4.1)	0.52
	2 or more Risk Factors	0.8	(0.3 - 2.3)	0.68	1.3	(0.5 - 3.7)	0.63
Obese	No	Reference			Reference		
	Yes	1.0	(0.6 - 1.7)	0.95	1.4	(0.8 - 2.6)	0.26
Cardiovascular disease	No	Reference			Reference		
	Yes	0.9	(0.2 - 3.1)	0.81	0.5	(0.1 - 3.8)	0.47
Diabetes	No	Reference			Reference		
	Yes	1.2	(0.6 - 2.5)	0.53	0.8	(0.3 - 2.1)	0.71
Chronic Pulmonary Disease	No	Reference			Reference		
	Yes	0.4	(0.0 - 2.7)	0.32	0.6	(0.1 - 5.0)	0.64
High Risk Prostate Cancer	No	Reference			Reference		
	Yes	2.3	(1.3 - 3.9)	<0.001	3.0	(1.6 - 5.5)	<0.001
PSA at Biopsy		1.0	(1.0 - 1.0)	0.79	1.0	(0.9 - 1.0)	0.20
Clinical T Stage	I	Reference			Reference		
	II	1.2	(0.6 - 2.2)	0.63	1.0	(0.4 - 2.4)	0.95
	III	---			1.6	(0.4 - 6.5)	0.48
	IV	----			----		
Biopsy Gleason Grade Group	1	Reference			Reference		
	2	3.8	(1.5 - 9.8)	0.01	2.0	(0.6 - 6.7)	0.27
	3	3.1	(1.1 - 8.6)	0.03	4.8	(1.5 - 15.7)	0.01
	4 & 5	6.2	(2.4 - 15.9)	<0.001	7.4	(2.4 - 23.0)	<0.001
MRI during Work Up	No	Reference			Reference		
	Yes	0.9	(0.5 - 1.6)	0.79	1.5	(0.8 - 2.8)	0.25
Outside Biopsy	No	Reference			Reference		
	Yes	2.1	(1.2 - 3.6)	0.01	3.6	(1.9 - 6.8)	<0.001
Time of First Encounter	Prior to Lockdown	----			Reference		
	During the Lockdown				1.5	(0.8 - 2.9)	0.22

eTable 3. Rates of Non-Surgical Treatment Prior to and During the 2020 Lockdown, by Race

Race	2019			2020		
	Black, Non-Hispanic	White, Non-Hispanic	p-value	Black, Non-Hispanic	White, Non-Hispanic	p-value
Active Surveillance	10 (12.7%)	17 (7.5%)	0.35	4 (5.3%)	7 (4.9%)	0.64
Radiation Therapy	2 (2.5%)	8 (3.5%)		1 (1.3%)	5 (3.5%)	